Invesco India Pharma and Healthcare Fund Regular Growth
NAV ₹10.54 on 13 November 2026
AMFI name: Invesco India Pharma and Healthcare Fund - Regular Plan - Growth · Scheme code 154545
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY HEALTHCARE INDEX TRI | Category median |
|---|---|---|---|
| 1M | +15.57% | +8.67% | +8.25% |
| 6M | - | +12.84% | +9.28% |
| 1Y | - | +38.92% | +4.48% |
| 3Y | - | +28.05% | +15.37% |
| 5Y | - | - | +13.85% |
Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare TRI, which we do not hold, so this is the closest NSE index.
Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.
Risk
From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.
- Max drawdown
- -11.50%
- Worst fall from a peak, 3 years
- Sortino ratio
- 2.33
- Like Sharpe, counting only falls, 3 years
- Alpha
- +6.16%
- Return a year beyond what beta explains, 3 years
- Beta
- 0.99
- 1.00 moves in step with the benchmark, 3 years
- Upside capture
- 104%
- Share of the benchmark's rises captured, 3 years
- Downside capture
- 99%
- Share of the benchmark's falls taken (lower is better), 3 years
Rank among peers
Regular plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.
| Rank | Scheme Name | 3Y Return | 1Y Return | Sharpe | Direct TER | AUM |
|---|---|---|---|---|---|---|
| #1 | Nippon India Mutual Fund | +46.52% | +60.64% | 1.07 | 1.06% | ₹1,100 Cr |
| #2 | HDFC Mutual Fund | +33.64% | +20.34% | 1.07 | 0.89% | ₹11,128 Cr |
| #3 | HDFC Mutual Fund | +31.28% | +31.60% | 1.76 | 1.03% | ₹3,128 Cr |
| #4 | SBI Mutual Fund | +25.42% | +26.07% | 1.47 | 0.76% | ₹5,565 Cr |
| #5 | HDFC Mutual Fund | +24.77% | +10.10% | 1.09 | 1.10% | ₹1,997 Cr |
| #6 | Mirae Asset Mutual Fund | +24.42% | +27.89% | 1.28 | - | ₹3,458 Cr |
| #7 | UTI Mutual Fund | +23.89% | +22.00% | 1.31 | 1.35% | ₹1,399 Cr |
| #8 | ICICI Prudential Mutual Fund | +22.73% | +10.29% | 0.95 | 2.08% | ₹3,926 Cr |
| #- | Invesco India Pharma and Healthcare FundCurrent Fund Invesco Mutual Fund | - | - | - | - | ₹111 Cr |
Costs and fund facts
- Exit load
- Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
- Fund size (all plans)
- ₹111 CrAverage, quarter to September 2026
- Benchmark
- BSE Healthcare TRICompared here with NIFTY HEALTHCARE INDEX TRI
- Allotment date
- 7 September 2026Scheme document
- Type
- An open ended equity scheme investing in Pharma, Healthcare and allied sectors
- AMFI scheme code
- 154545
Fund manager
- Aditya Khemanisince 07-Sep-2026
How each manager has done since taking over: fund manager scorecard.
Investment objective
To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
About this fund
Invesco India Pharma and Healthcare Fund Regular Growth is a mutual fund scheme from Invesco Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Regular plan with the Growth option. Its NAV was ₹10.54 on 13 November 2026. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹111 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Managed by Aditya Khemani. Its scheme summary document gives the allotment date as 7 September 2026.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.